Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 15, Issue 1-3, Pages 79-84
http://dx.doi.org/10.1155/1999/278269

BRCA1 1675delA and 1135insA Account for One Third of Norwegian Familial Breast-Ovarian Cancer and Are Associated with Later Disease Onset than Less Frequent Mutations

Åke Borg,1 Anne Dørum,2 Ketil Heimdal,2 Lovise Mæhle,2 Eivind Hovig,3 and Pål Møller2

1Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
2Unit of Medical Genetics, The Norwegian Radium Hospital, N-0310 Oslo, Norway
3Department of Tumour Biology, The Norwegian Radium Hospital, N-0310 Oslo, Norway

Received 9 December 1999; Accepted 9 December 1999

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [23 citations]

The following is the list of published articles that have cited the current article.

  • M. Steel, “Familial Breast Cancer: The Problems of Circumstantial Evidence,” Clinical Oncology, vol. 12, no. 5, pp. 298–299, 2000. View at Publisher · View at Google Scholar
  • Sl Neuhausen, “Founder populations and their uses for breast cancer genetics,” Breast Cancer Research, vol. 2, no. 2, pp. 77–81, 2000. View at Publisher · View at Google Scholar
  • E Hovig, A Borg, J Apold, K Heimdal, P Moller, J Vallon-Christersson, and L Maehle, “The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series,” European Journal Of Cancer, vol. 37, no. 8, pp. 1027–1032, 2001. View at Publisher · View at Google Scholar
  • Km Tveit, Al Borresen-Dale, Jc Pedersen, P Kringen, Ti Andersen, K Berg, S Egedal, and Tb Haribtz, “BRCA1 mutation screening using restriction endonuclase fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system,” Electrophoresis, vol. 23, no. 24, pp. 4085–4091, 2002. View at Publisher · View at Google Scholar
  • K Heimdal, P Moller, and E Skovlund, “Oral contraceptives and risk of familial breast cancer,” Cancer Detection And Prevention, vol. 26, no. 1, pp. 23–27, 2002. View at Publisher · View at Google Scholar
  • T Bjorge, Po Ekstrom, E Hovig, S Hansen, A Dorum, As Longva, Km Heintz, Re Gislefoss, and Dj Warren, “Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis,” Analytical Chemistry, vol. 76, no. 15, pp. 4406–4409, 2004. View at Publisher · View at Google Scholar
  • A Dorum, S Hansen, E Jellum, H Langseth, K Nustad, Re Gislefoss, T Bjorge, Cg Trope, Ak Lie, and E Hovig, “BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study,” British Journal Of Cancer, vol. 91, no. 10, pp. 1829–1834, 2004. View at Publisher · View at Google Scholar
  • Albert Altchek, “Clues to Tumors,” Diagnosis and Management of Ovarian Disorders, pp. 231–269, 2004. View at Publisher · View at Google Scholar
  • Murray Casey, and Chhanda Bewtra, “Peritoneal carcinoma in women with genetic susceptibility: Implications for Jewish populations,” Familial Cancer, vol. 3, no. 3-4, pp. 265–281, 2004. View at Publisher · View at Google Scholar
  • P Kringen, G Kristensen, Jm Nesland, A Dorum, V Dumeaux, Y Wang, and Al Borresen-Dale, “TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival,” Bmc Cancer, vol. 5, 2005. View at Publisher · View at Google Scholar
  • A Jugessur, P Frost, Hg Eiken, K Heimdal, T Aloysius, Ak Eliassen, J Apold, L Fauske, and G Matre, “Complete mutation screening and haplotype characterization of the BRCA1 gene in 61 familial breast cancer patients from Norway,” Disease Markers, vol. 21, no. 1, pp. 29–36, 2005. View at Publisher · View at Google Scholar
  • Ta Kruse, M Thomassen, Dg Cruger, and Am Gerdes, “Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families,” Clinical Genetics, vol. 69, no. 2, pp. 171–178, 2006. View at Publisher · View at Google Scholar
  • Anne-Marie Gerdes, Cruger, Thomassen, and Kruse, “Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families,” Clinical Genetics, vol. 69, no. 2, pp. 171–178, 2006. View at Publisher · View at Google Scholar
  • G Dekomien, M Kurz, Jt Epplen, Jp Larsen, D Woitalla, T Muller, and Am Schlitter, “Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts,” Acta Neurologica Scandinavica, vol. 113, no. 1, pp. 9–13, 2006. View at Publisher · View at Google Scholar
  • Jill Stopfer, Bernard A. Mason, Katherine L. Nathanson, Jessica Tigges-Cardwell, Jill D. Siegfried, Julie Erlichman, Susan M. Domchek, Timothy R. Rebbeck, and Maurizia Dalla Palma, “The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families,” Cancer Research, vol. 68, no. 17, pp. 7006–7014, 2008. View at Publisher · View at Google Scholar
  • George Fountzilas, George Nounesis, Angela Ladopoulou, Vassiliki Gaki, Irene Konstantopoulou, Drakoulis Yannoukakos, Theodore Rampias, Dimosthenis Skarlos, Antonis Stylianakis, George Koutsodontis, George Nikolopoulos, Antonios Keramopoulos, Nikos Pandis, Evangelia Razis, Sophia Armaou, Helen Gogas, Theodore Anagnostopoulos, Charisios Karanikiotis, Iordanis Arzimanoglou, Christos Markopoulos, Thalia Bei, and Smaragda Kamakari, “Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients,” Breast Cancer Research And Treatment, vol. 107, no. 3, pp. 431–441, 2008. View at Publisher · View at Google Scholar
  • Finn C. Nielsen, Torben A. Kruse, Thomas V. O. Hansen, Anne-Marie Gerdes, Friedrik Wikman, Ake Borg, Inge Sokilde Pedersen, Marie Luise Bisgaard, Henriette Theilmann Lianee, and Mads Thomassen, “BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer,” Acta Oncologica, vol. 47, no. 4, pp. 772–777, 2008. View at Publisher · View at Google Scholar
  • Ramunas Janavičius, “Founder BRCA1/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control,” EPMA Journal, vol. 1, no. 3, pp. 397–412, 2010. View at Publisher · View at Google Scholar
  • Marion Drusedau, Jos C. Dreesen, Inge Derks-Smeets, Edith Coonen, Ron van Golde, Jannie van Echten-Arends, Peter M. M. Kastrop, Marinus J. Blok, Encarna Gomez-Garcia, Joep P. Geraedts, Hubert J. Smeets, Christine E. de Die-Smulders, and Aimee D. Paulussen, “PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers,” European Journal of Human Genetics, vol. 21, no. 12, pp. 1361–1368, 2013. View at Publisher · View at Google Scholar
  • Ora Karp Gordon, “Cancer of the Breast and Female Reproductive Tract,” Emery and Rimoin's Principles and Practice of Medical Genetics, pp. 1–31, 2013. View at Publisher · View at Google Scholar
  • Anna Kluska, Aneta Balabas, Agnieszka Paziewska, Maria Kulecka, Dorota Nowakowska, Michal Mikula, and Jerzy Ostrowski, “New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing,” BMC Medical Genomics, vol. 8, no. 1, 2015. View at Publisher · View at Google Scholar
  • H Wu, X Wu, and Z Liang, “Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms,” Gene Therapy, 2017. View at Publisher · View at Google Scholar
  • Pål Møller, Mev Dominguez-Valentin, Einar Rødland, and Eivind Hovig, “Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift,” Cancers, vol. 11, no. 2, pp. 132, 2019. View at Publisher · View at Google Scholar